Bio-Rad Laboratories, Inc. (NYSE:BIO) is one of the best debt-free mid-cap stocks to buy according to hedge funds. On February 12, Bio-Rad Laboratories, Inc. (NYSE:BIO) delivered solid fourth-quarter ...
Bio-Rad Laboratories Inc. (NYSE: BIO and BIOb) today announced the launch of the ChemiDoc MP Digital Imaging System. The imager combines the industry’s best performance with ease of use and is ideal ...
Q4 2025 Net Sales: $693 million, a 3.9% increase from Q4 2024. Q4 2025 Gross Margin: 49.8% GAAP, 52.5% non-GAAP. Q4 2025 Operating Loss: $119 million, including $173 million in impairment charges. Q4 ...
In this article, we will be taking a look at the 13 Most Oversold Healthcare Stocks So Far in 2025. Bio-Rad Laboratories, Inc. stands amongst them. Bio-Rad Laboratories, Inc. (NYSE:BIO), a global ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results